Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors
July 17 2018 - 4:05PM
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
the election of Jeryl Hilleman to the Board of Directors of the
Company.
“Jeri brings a broad life sciences background to Minerva that
includes high growth commercial biopharma, med-tech and data
science companies,” said William F. Doyle, Lead Independent
Director of Minerva. “Her track record of delivering
strategic and financial growth through execution, strategic
partnering and multiple acquisitions will serve Minerva well as the
Company completes five ongoing late-stage clinical trials with
roluperidone, seltorexant and MIN-117.”
Ms. Hilleman is presently Chief Financial
Officer of Intersect ENT (NASDAQ:XENT), a medical device company
with commercial products for the treatment of chronic
sinusitis. Previously, she served as CFO of several public
companies, including Amyris, a renewable products company, Symyx
Technologies (acquired), which provided research services, software
and instrumentation, Ocera (acquired), a biopharma company, and
Cytel (acquired), an immunotherapy company. Ms. Hilleman served as
a member of the Board of Directors and Chair of the Audit Committee
of Xenoport, Inc. (acquired), a commercial biopharma company, for
over ten years, from IPO through acquisition. Ms. Hilleman holds an
A.B. from Brown University and an M.B.A. from the Wharton Graduate
School of Business. She is a member of the 1999 class of Henry
Crown Fellows and the Aspen Global Leadership Network at the Aspen
Institute.
About Minerva Neurosciences:
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of product candidates to treat CNS
diseases. Minerva’s proprietary compounds include:
roluperidone (MIN-101), in clinical development for schizophrenia;
MIN-117, in clinical development for major depressive disorder
(MDD); seltorexant (MIN-202 or JNJ-42847922), in clinical
development for insomnia and MDD; and MIN-301, in pre-clinical
development for Parkinson’s disease. Minerva’s common stock
is listed on the NASDAQ Global Market under the symbol
“NERV.” For more information, please
visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor Statement
This press release contains forward-looking statements which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking
statements are statements that are not historical facts, reflect
management’s expectations as of the date of this press release, and
involve certain risks and uncertainties. Forward-looking
statements include statements herein with respect to Ms. Hilleman’s
positive impact on us, including as we proceed through clinical
trials. These forward-looking statements are based on our
current expectations and may differ materially from actual results
due to a variety of factors including, without limitation, Ms.
Hilleman’s and our ability to perform as expected. These and
other potential risks and uncertainties that could cause actual
results to differ from the results predicted are more fully
detailed under the caption “Risk Factors” in our filings with the
Securities and Exchange Commission, including our Quarterly Report
on Form 10-Q for the quarter ended March 31, 2018, filed with
the Securities and Exchange Commission on May 3, 2018.
Copies of reports filed with the SEC are posted on our
website at www.minervaneurosciences.com. The forward-looking
statements in this press release are based on information available
to us as of the date hereof, and we disclaim any obligation to
update any forward-looking statements, except as required by
law.
Contact:
William B. BoniVP, Investor Relations/Corp.
CommunicationsMinerva Neurosciences, Inc.(617) 600-7376
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024